As of 2025-09-17, the Intrinsic Value of GT Biopharma Inc (GTBP) is -16.39 USD. This GTBP valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.83 USD, the upside of GT Biopharma Inc is -2,087.06%.
Based on its market price of 0.83 USD and our intrinsic valuation, GT Biopharma Inc (GTBP) is overvalued by 2,087.06%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -16.39 - -16.39 | -16.39 | -2,087.06% |
| P/E | (39.67) - (56.06) | (44.75) | -5524.7% |
| DDM - Stable | (21.65) - (75.06) | (48.35) | -5961.0% |
| DDM - Multi | (21.39) - (60.30) | (31.88) | -3964.1% |
| Market Cap (mil) | 2.94 |
| Beta | 0.36 |
| Outstanding shares (mil) | 3.56 |
| Enterprise Value (mil) | -2.29 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.27% |
| Cost of Debt | 5.00% |
| WACC | 7.47% |